Recro Pharma (REPH) Tops Q4 EPS by 17c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
February 19, 2019 7:01 AM ESTMarch 24, 2019 PDUFA Goal Date for IV Meloxicam
Record CDMO Performance; 2018 Revenues of $77.3 Million
Company to Host Conference Call Today at 8:00 AM ET
MALVERN, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ: REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the fourth quarter and year ended December 31, 2018.
As we await the upcoming review decision from the U.S. Food and Drug Administration... More
